Designing and delivering cell therapies to transform the lives of people with cancer.
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.
An industry leading TCR pipeline that targets solid tumors
We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.
Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.